Mukul Agrawal stock, specializing in the research, development, manufacture, and commercialization of biological drug products in various injectable formats, jumped upto 5 percent following the bulk deal involving Motilal Oswal Mutual Fund
Price action
With a market capitalization of Rs.18,008 crores on Monday, the shares of OneSource Specialty Pharma Limited were down by 4.5 percent in Intraday’s trade making a low of Rs. 1,427.45 per share and compared to the closing price of Rs. 1,502.45 per share.
What Happened
OneSource Specialty Pharma Limited, a company specializing in the research, development, manufacture, and commercialization of biological drug products, recently experienced a bulk deal in which Motilal Oswal Mutual Fund A/C Motilal Oswal Large and Midcap Fund purchased a 0.92 percent stake. In this transaction, 10.55 lakh shares were purchased at Rs. 1,545 each, resulting in a total value of around Rs. 163 Crores.
About the Company
OneSource Specialty Pharma Limited is a global pharmaceutical company specializing in the development, manufacturing, and commercialization of niche and complex medicines. The company focuses on providing high-quality specialty drugs in therapeutic areas like oncology, neurology, and infectious diseases.
Ace Investor
Ace Investor Mukul Mahavir Agrawal holds 16,30,147 shares in the company which consists of a 1.42 stake as of December 2024.
Financials
The company’s revenue rose by 496 percent from Rs. 57.32 crore to Rs. 341.76 crore in Q3FY24-25. Meanwhile, Net loss reduced from a loss of Rs. 130 crore to a loss of Rs. 73.02 crore during the same period.
Written by Sridhar J
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
